Autolus Therapeutics

1.45
0.02 (1.40%)
At close: Apr 21, 2025, 3:59 PM
1.45
0.35%
Pre-market: Apr 22, 2025, 04:02 AM EDT
1.40%
Bid 1.44
Market Cap 384.55M
Revenue (ttm) 10.12M
Net Income (ttm) -220.66M
EPS (ttm) -0.86
PE Ratio (ttm) -1.68
Forward PE -1.99
Analyst Buy
Ask 1.5
Volume 1,381,722
Avg. Volume (20D) 1,462,085
Open 1.34
Previous Close 1.43
Day's Range 1.41 - 1.53
52-Week Range 1.10 - 5.00
Beta 2.06

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a program...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2018
Employees 647
Stock Exchange NASDAQ
Ticker Symbol AUTL
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 592.04% from the latest price.

Stock Forecasts

Next Earnings Release

Autolus Therapeutics is scheduled to release its earnings on May 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-9.03%
Autolus Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
1 month ago
-13.4%
Autolus Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.